Oruka Therapeutics, Inc.
NASDAQ:ORKABiotechnology
+$0.46 today
- Market cap
- $6.49B
- Beta
- -0.30
- P/E (TTM)
- -33.9
- EPS (TTM)
- -$2.11
Volume 0.52M
Average 1.55M
ORKA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Oruka Therapeutics, Inc.NASDAQ: ORKA
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development growth accelerates
Q3 FY2026 research & development of $53.7M rose 85.2% year over year, ahead of the +46.0% change in trailing-twelve-month research & development. Sequentially, it rose 24.1% from the prior quarter. Over 3 fiscal years it compounded at +182.5% a year.
Context
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +85.2% holds above the trailing-twelve-month pace of +46.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 100.64M USD
- Year-over-year change
- +34.1%
- 4-year CAGR
- +64.2%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 100.64M | +34.1% |
| FY2024 | 2024-12-31 | 75.06M | +7309.7% |
| FY2023 | 2023-12-31 | 1.01M | -77.3% |
| FY2022 | 2022-12-31 | 4.46M | -67.7% |
| FY2021 | 2021-12-31 | 13.83M | — |
Research & Development vs competitors
How ORKA compares with its peers on the latest reported figures
- ORKA's LTM Sep 2026 research & development of $153.74M is the 5th highest of the 10 companies compared; the peer median is $128.65M.
- Its year-over-year change of +46.0% is the 6th highest of 10, against a peer median of +48.2%.
- Over three fiscal years its annual growth of +182.5% compares with a peer median of +18.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $346.63M | -8.7% | +56.3% | 4685.4% |
| LTM Jun 2026 | $255.77M | +11.4% | +6.3% | 243.6% | |
| LTM Mar 2026 | $220.82M | +62.1% | +69.0% | — | |
| LTM Jun 2026 | $175.6M | +66.9% | +70.5% | 9222.6% | |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | $153.74M | +46.0% | +182.5% | — |
| LTM Mar 2026 | $128.65M | -23.4% | +15.3% | 55.4% | |
| LTM Mar 2026 | $56.72M | +60.6% | -12.2% | 677.9% | |
| FY2025 | $54.15M | +59.9% | — | 4011.3% | |
ZURAZura Bio Limited | LTM Mar 2026 | $46.35M | +48.2% | +21.1% | — |
| FY2025 | $37.8M | +29.2% | -26.9% | 59059.4% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ORKA) | $128.65M | +48.2% | +18.2% | 4011.3% | |
Competitors are the stored peer set for ORKA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 91K | 114K | 111K | 27K | 83K |
| Gross Profit | (91K) | (114K) | (111K) | (27K) | (83K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 13.83M | 4.46M | 1.01M | 75.06M | 100.64M |
| Selling, General & Admin | 5.41M | 5.26M | 6.17M | 13.04M | 21.33M |
| Operating Expenses | 19.24M | 9.73M | 7.19M | 88.1M | 121.97M |
| Depreciation & Amortization | 91K | 114K | 111K | 27K | 83K |
| EBITDA | (19.23M) | (9.81M) | (5.23M) | (82.23M) | (105.35M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (19.34M) | (9.84M) | (7.3M) | (88.12M) | (122.05M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 675K | 1.96M | 5.86M | 16.63M |
| Interest Expense | 0 | 0 | 0 | 1.47M | 0 |
| Other Income / Expenses | 13K | (85K) | 1.96M | 4.4M | 16.62M |
| Income Before Tax | (19.32M) | (9.93M) | (5.34M) | (83.72M) | (105.43M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (19.32M) | (9.93M) | (5.34M) | (83.72M) | (105.43M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (16.68) | (8.27) | (4.44) | (4.99) | (2.31) |
| EPS (Diluted) | (16.68) | (8.27) | (4.44) | (4.99) | (2.31) |
| Weighted Avg Shares | 13.9M | 14.41M | 14.42M | 16.79M | 45.61M |
| Weighted Avg Shares (Diluted) | 13.9M | 14.41M | 14.42M | 16.79M | 45.61M |
Oruka Therapeutics, Inc.
NASDAQ:ORKA
Intrinsic Alpha fair value
Locked
Current Price
$95.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.